Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NIH to Study Three Drugs in Treatment of Covid-19 Patients

10/16/2020 | 07:45am EST

By Thomas M. Burton

WASHINGTON -- The National Institutes of Health is launching a late-stage clinical trial to determine whether three drugs used for controlling immune systems could be used to treat respiratory distress and organ failure in severely ill Covid-19 patients.

The NIH study will evaluate two drugs already on the market, Johnson & Johnson's Remicade and Bristol-Myers Squibb Co.'s Orencia, along with an investigational drug called CVC from AbbVie Inc.

The study will evaluate whether any of the medicines, known as immune modulators, can control an overreaction of the patient's systemic Covid-19 inflammatory response.

This phenomenon, known as a "cytokine storm" for the proteins that trigger the inflammation, can lead to respiratory distress, multiple organ failure and other severe reactions in hospitalized patients. Cytokines are part of the body's normal immune reaction, but one that in this instance has gone haywire.

The study, at sites in the U.S. and Latin America, is expected to last up to eight months and will enroll about 2,100 patients. All of the patients will receive the standard-treatment antiviral drug remdesivir.

Some will also get a placebo, while others will also get one of the drugs being studied. The study will evaluate whether the study drugs lower severity of disease, recovery time, death rate and use of hospital resources.

Write to Thomas M. Burton at tom.burton@wsj.com

(END) Dow Jones Newswires

10-16-20 0744ET

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 1.37% 106.03 Delayed Quote.18.30%
BRISTOL-MYERS SQUIBB COMPANY -0.64% 62.06 Delayed Quote.-3.13%
JOHNSON & JOHNSON 0.58% 149.69 Delayed Quote.2.15%
All news about JOHNSON & JOHNSON
09:17aJOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA Seeking Approval of ..
AQ
08:35aIMPACT DURING A PANDEMIC : 5 Ways Johnson & Johnson Was Recognized for Its COVID..
PU
12/03JOHNSON & JOHNSON : Janssen Headlines American Society of Hematology Annual Meet..
PU
12/03JOHNSON & JOHNSON : Change in Directors or Principal Officers (form 8-K)
AQ
12/03JOHNSON & JOHNSON : Names Dr. Nadja West, retired United States Army lieutenant ..
PR
12/03JOHNSON & JOHNSON : J&J Unit Seeks FDA OK of Amivantamab in Form of Non-Small Ce..
DJ
12/03JOHNSON & JOHNSON : Announces Fireside Chat Webcast on Janssen's Eye Disease Por..
PU
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/02HOFSETH BIOCARE ASA : HBC adds ex-Johnson & Johnson Senior Commercial leader, Wi..
AQ
More news
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 24,5x
Yield 2020 2,66%
Capitalization 392 B 392 B -
EV / Sales 2020 4,88x
EV / Sales 2021 4,42x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 164,73 $
Last Close Price 149,00 $
Spread / Highest target 20,8%
Spread / Average Target 10,6%
Spread / Lowest Target -6,71%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071
ABBVIE INC.18.30%184 916